SCHEMBL30730632

SCHEMBL30730632

Cc1nonc1CC(=O)N1CCC(O)(c2nc(-c3ccc(F)cc3)no2)CC1

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 5/20 0.45
ALOX15 P16050 1/20 0.45
TSHR P16473 1/20 0.45
MAPK1 P28482 1/20 0.45
KMT2A Q03164 3/20 0.44
MEN1 O00255 2/20 0.44
RAB9A P51151 1/20 0.44
ALDH1A1 P00352 4/20 0.42
RORC P51449 1/20 0.41
HDAC4 P56524 2/20 0.41
HDAC6 Q9UBN7 2/20 0.41
PKM P14618 1/20 0.39
HPGD P15428 1/20 0.39
POLB P06746 1/20 0.38
DGAT1 O75907 1/20 0.38
TACR3 P29371 1/20 0.38
GRM5 P41594 1/20 0.37
CLPP Q16740 1/20 0.37
HSD11B1 P28845 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30730515 0.90 LMNA (0.45) LMNAALOX15TSHRMAPK1KMT2A
SCHEMBL32677165 0.88 LMNA (0.43) LMNAALOX15TSHRMAPK1KMT2A
SCHEMBL30730643 0.86 RAB9A (0.42) LMNATSHRKMT2AMEN1RAB9A
SCHEMBL30730633 0.85 LMNA (0.45) LMNAALOX15TSHRMAPK1KMT2A
SCHEMBL30730477 0.81 LMNA (0.55) LMNAALOX15TSHRMAPK1KMT2A
SCHEMBL30730653 0.81 LMNA (0.53) LMNAALOX15TSHRMAPK1KMT2A
SCHEMBL30730475 0.81 LMNA (0.51) LMNAALOX15TSHRMAPK1KMT2A
SCHEMBL30730427 0.81 LMNA (0.54) LMNAALOX15TSHRMAPK1ALDH1A1
SCHEMBL30730662 0.80 LMNA (0.71) LMNAALOX15TSHRMAPK1KMT2A
SCHEMBL30730465 0.77 TSHR (0.56) LMNAALOX15TSHRMAPK1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260048047-A1 SMALL-MOLECULE ACTIVATORS OF MYCOBACTERIUM TUBERCULOSIS ADENYLYL CYCLASE SCRIPPS RESEARCH INST (US) 2026-02-19 US claimed
WO-2024030121-A1 SMALL-MOLECULE ACTIVATORS OF MYCOBACTERIUM TUBERCULOSIS ADENYLYL CYCLASE THE SCRIPPS RESEARCH INSTITUTE (US) 2024-02-08 WO claimed
US-20260048047-A1 SMALL-MOLECULE ACTIVATORS OF MYCOBACTERIUM TUBERCULOSIS ADENYLYL CYCLASE SCRIPPS RESEARCH INST (US) 2026-02-19 US disclosed
WO-2024030121-A1 SMALL-MOLECULE ACTIVATORS OF MYCOBACTERIUM TUBERCULOSIS ADENYLYL CYCLASE THE SCRIPPS RESEARCH INSTITUTE (US) 2024-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260048047-A1 SMALL-MOLECULE ACTIVATORS OF MYCOBACTERIUM TUBERCULOSIS ADENYLYL CYCLASE FNTB, PDE7A, TBL3 LMNA 1838/4885ALOX15 2647/4885TSHR 620/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.